Rompag — Eltrombopag 50 mg

Rompag 50 is supplied as film-coated tablets intended for oral intake. The formulation consists of:

• Active Ingredient (per 1 tablet): Eltrombopag olamine (equivalent to eltrombopag) — 50 mg.
• Inactive Excipients: Microcrystalline cellulose, lactose monohydrate, magnesium stearate, sodium starch glycolate, povidone, alongside film coating materials (hypromellose, titanium dioxide, macrogol, iron oxide color agents).
• Dosage Form and Format: Circular tablets. Packaged into original cardboard retail cartons enclosing 28 tablets total (4 internal structural cards holding 7 tablets each) paired with an authorized medical information leaflet.

Pharmacodynamics: Eltrombopag is an orally active, non-peptide TPO receptor agonist. It interacts directly with the transmembrane domain of the human thrombopoietin receptor, initiating intracellular signaling cascades identical to endogenous thrombopoietin (specifically the JAK/STAT signaling pathways). This mechanism accelerates bone marrow cell maturation, inducing a significant rise in platelet numbers without stimulating platelet aggregation.

Pharmacokinetics: Following oral administration, the maximum plasma concentration (Cmax) of eltrombopag is reached within 2 to 6 hours. Systemic absorption is heavily diminished when taken concurrently with high-calcium meals or antacid suspensions. Plasma protein binding exceeds 99%. The drug is extensively metabolized in the liver via oxidative and conjugation pathways. The elimination half-life (T1/2) ranges from 21 to 35 hours. Excretion is primarily fecal (approx. 59%) and renal (approx. 31%).

Rompag 50 mg tablets are indicated for adult and pediatric treatment programs, either as monotherapy or within multi-agent setups, for the following conditions:

• 🔹 Immune Thrombocytopenia (ITP): Chronic immune (idiopathic) thrombocytopenic purpura management in patient groups non-responsive to baseline interventions (e.g., corticosteroids, immunoglobulins).
• 🔹 Thrombocytopenia in Hepatitis C: Severe thrombocytopenia management in chronic hepatitis C patients to enable initiation and optimization of interferon-based antiviral therapy courses.
• 🔹 Aplastic Anemia: Severe acquired aplastic anemia therapy in individuals showing resistance or inadequate response to previous immunosuppressive regimens.

The dosing instructions for Rompag 50 are customized by the managing clinician based on blood count dynamics and targeted platelet targets. Tablets are ingested orally, swallowed whole:

• Administration Guidelines (CRITICAL): Take the medication at least 1 hour prior to or 2 hours following meals. Crucially, eltrombopag must be taken at least 2 hours before or 4 hours after consuming products such as antacids, dairy items, or mineral supplements containing polyvalent cations (calcium, magnesium, iron, selenium, zinc). Violating this timeline severely drops compound absorption.
• Standard Treatment Protocols: For ITP, the regular initial dose is 50 mg (1 tablet) once per day. For individuals of East Asian ancestry, the initial dosage is adjusted down to 25 mg daily. Gradual dose adjustments are implemented (no more than once every 1–2 weeks) to hold platelet volumes within a safe margin (≥ 50,000/μL).
• Maximum Limit: The total daily dose of Rompag must never exceed 75 mg.

The therapeutic use of Rompag 50 tablets is contraindicated in the presence of the following medical contexts:

• ⛔ Hypersensitivity: Individual systemic intolerance to eltrombopag or any baseline inactive component within the tablet structure.
• ⛔ Severe Hepatic Insufficiency: Severe liver function impairments (Child-Pugh Class C), unless specifically deployed for Hepatitis C-associated thrombocytopenia under highly rigid supervision.
• ⛔ Thrombophilia and Thromboembolism: High baseline risk of thromboembolic events or recent active thrombotic occurrences in the patient's anamnesis.
• ⛔ Pregnancy and Lactation: Periods of pregnancy or active breastfeeding.
• ⚠️ With Caution: Exercise care in individuals with chronic kidney disease, active cataracts, thrombotic predispositions, or genetic indicators pointing toward myelodysplastic syndrome.

Eltrombopag participates in cross-reactive drug pathways that can alter systemic concentrations or inhibit therapeutic values:

• ❌ Polyvalent Cations (Antacids, Minerals): Calcium, magnesium, aluminum, iron, and zinc formulations create non-absorbable chelate compounds with eltrombopag in the digestive tract, blocking its clinical entry.
• ❌ Statins (HMG-CoA Reductase Inhibitors): Rompag significantly escalates the systemic exposure profiles of statins (such as rosuvastatin or atorvastatin), increasing risks of myopathy and rhabdomyolysis. Statin dose rollbacks are required.
• ❌ Transporter Inhibitors and Inducers: Agents interacting with OATP1B1 and BCRP transporter systems can modify eltrombopag plasma parameters.

Reproductive parameters and safety boundaries for Rompag 50:

• Pregnancy: Adequate clinical data on eltrombopag use during human gestation is unavailable. Animal reproductive evaluations demonstrated embryofetal toxicity lines. The medication is contraindicated during pregnancy. Women of childbearing potential must deploy highly reliable contraceptive steps during therapy and for 2 weeks post-discontinuation.
• Lactation: It is unverified if eltrombopag partitions into human breast milk. If Rompag use becomes clinically unavoidable, breastfeeding routines must be fully terminated.
• Fertility: The product exhibits no direct damaging consequences on male or female fertility criteria when therapeutic dose boundaries are strictly maintained.

Rompag 50 treatment cycles necessitate continuous laboratory blood evaluations due to potential adverse reactions:

• 🟢 Gastrointestinal and Systemic Manifestations: Nausea, diarrhea, vomiting, dry mouth, abdominal pain, chronic fatigue, influenza-like states, and sleep architecture disturbances.
• 🟡 Hepatic Toxicity (CRITICAL): Elevations in transaminase markers (ALT, AST) and total bilirubin volumes. Monthly (or weekly during initiation) hepatic screening is mandatory.
• 🟠 Thromboembolic Events: Elevated risks of deep vein thrombosis, pulmonary embolism, or portal vein occlusion, particularly during sharp, unchecked climbs in platelet populations.
• 🔵 Other Reactions: Development or worsening of cataracts, skin rash manifestations, alopecia, myalgia, and localized paresthesia.

Exceeding recommended eltrombopag dosages creates immediate life-threatening conditions due to acute blood viscosity increases:

• Symptomatology: Overdose situations prompt an excessive, rapid surge in platelet populations, creating high risks for acute thromboembolic emergencies (myocardial infarction, stroke, deep venous occlusion). General systemic toxemia signs, headache, and severe skin eruptions can also develop.
• Management: No specific antidote is available. In the event of an overdose, cease medication intake instantly, administer oral enterosorbents (if detected early), and execute emergency hospitalization to track blood properties. Oral calcium administration can be considered to minimize the systemic absorption of remaining gastrointestinal drug volumes.

To preserve the structural integrity and potency of Rompag 50 tablets, implement the following warehouse baselines:

• 🌡️ Temperature Parameters: Keep within the original factory box in a dry space shielded from light exposure at a temperature not exceeding 30 °C.
• 👶 Safety Demands: The medicinal package must be kept entirely out of reach and sight of children and domestic animals.
• 📦 Package Wholeness: Do not separate internal packaging structures from the outer cardboard box until actual intake occurs. Storing exposed tablets outside their protective factory housing is forbidden.
• ⏳ Shelf Duration: 3 years from the production stamp. Do not ingest the medication after the official expiration date printed by Hetero Healthcare on the side panel of the box.